High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C
Joint Authors
Moghaddam, Mustafa Alavi
Zali, Muhammad Rida
Andabili, Sayyid Husayn Aalaei
Derakhshan, Faramarz
Miri, Sayyid Muhammad
Alavian, Sayyid Muayyad
Source
Iranian Red Crescent Medical Journal
Issue
Vol. 14, Issue 8 (31 Aug. 2012), pp.466-469, 4 p.
Publisher
Publication Date
2012-08-31
Country of Publication
United Arab Emirates
No. of Pages
4
Main Subjects
Topics
Abstract EN
Background : hepatitis C is a major reason of morbidity and mortality among hemophilia patients.
Although combination therapy with peg interferon (peg-INF) and ribavirin is considered as standard treatment for chronic hepatitis C (CHC), but more evidence of the efficacy and safety is needed.
Objectives : in this study, efficacy and tolerability of combination therapy with peg interferon α-2a–ribavirin was investigated among hemophilia HCV infected patients Patients and Materials : in a quasi-experimental, 45 naive hemophilia patients with chronic HCV received 180 mg of paginated interferon (Pegasus) by subcutaneous injection weekly plus an oral dose of 800-1200 μg ribavirin daily according to body weight.
The treatment continued 48 weeks in patients with genotype one and 24 weeks in those with genotype 3.
Sustained biological response (SVR) was considered as efficacy of treatment.
Result: Forty three patients (95.6 %) reached to end of treatment response (ETR) ; only two (4.4 %) patients did not respond and were discontinued from treatment.
None of 43 patients relapsed.
SVR obtained in 43 of 45 patients (95.6 %), in multivariate logistic regression model, third month’s treatment WBC (WBC > 2000) remained the only significant predictor of SVR.
Regimen dose reduced in three patients ; two of those because of ALT increasing and other one for his retinal bleeding.
In repeated measurement analysis, alanine aminotransferase (ALT) and hemoglobin (Hb) decreased significantly during treatment, but reduction of platelet (PLT) was not significant.
Conclusions : results show high efficacy and safety of combination therapy of Peg-IFN-α 2a plus ribavirin among hemophiliacs with chronic hepatitis C.
American Psychological Association (APA)
Moghaddam, Mustafa Alavi& Zali, Muhammad Rida& Andabili, Sayyid Husayn Aalaei& Derakhshan, Faramarz& Miri, Sayyid Muhammad& Alavian, Sayyid Muayyad. 2012. High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C. Iranian Red Crescent Medical Journal،Vol. 14, no. 8, pp.466-469.
https://search.emarefa.net/detail/BIM-311660
Modern Language Association (MLA)
Moghaddam, Mustafa Alavi…[et al.]. High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C. Iranian Red Crescent Medical Journal Vol. 14, no. 8 (Aug. 2012), pp.466-469.
https://search.emarefa.net/detail/BIM-311660
American Medical Association (AMA)
Moghaddam, Mustafa Alavi& Zali, Muhammad Rida& Andabili, Sayyid Husayn Aalaei& Derakhshan, Faramarz& Miri, Sayyid Muhammad& Alavian, Sayyid Muayyad. High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C. Iranian Red Crescent Medical Journal. 2012. Vol. 14, no. 8, pp.466-469.
https://search.emarefa.net/detail/BIM-311660
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 469
Record ID
BIM-311660